{"title":"呼吸和瓶子：评估酒精使用障碍的药物治疗对COPD加重结果的影响。","authors":"Teng Zhang, Qin Ding, Mengmeng Liu, Yanning Song, Lvfeng Zhang, Na Liang, Xia Zhao, Qian Wang, Xueli Guo, Guangmei Yang, Hongwei Zhang, Wei Chen","doi":"10.2147/COPD.S524905","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The role of pharmacotherapy for alcohol use disorder (AUD) in mitigating COPD exacerbations remains underexplored. This study aims to evaluate the impact of AUD pharmacotherapy on COPD-related clinical outcomes.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted on 635 COPD patients with comorbid AUD. Patients were categorized into two groups based on whether they received medication for AUD (MAUD group) or not (no-MAUD group). Data on demographics, COPD severity, exacerbation rates, and AUD treatment were extracted from electronic medical records.</p><p><strong>Results: </strong>Individuals in the MAUD group (n=229) exhibited a substantially reduced frequency of COPD exacerbations when compared to those in the non-MAUD group (n=406), with a significant difference observed (<i>P</i><0.001). Additionally, the MAUD group experienced a longer duration before the first exacerbation event (<i>P</i><0.001).</p><p><strong>Conclusion: </strong>Pharmacotherapy for AUD appears to have a protective effect against the occurrence of COPD exacerbations and improved clinical outcomes in patients with comorbid AUD. These findings suggest that AUD treatment should be considered as part of a comprehensive management strategy for COPD patients with AUD.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2697-2704"},"PeriodicalIF":3.1000,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333649/pdf/","citationCount":"0","resultStr":"{\"title\":\"Breath and Bottle: Evaluating Pharmacotherapy for Alcohol Use Disorder on COPD Exacerbation Outcomes.\",\"authors\":\"Teng Zhang, Qin Ding, Mengmeng Liu, Yanning Song, Lvfeng Zhang, Na Liang, Xia Zhao, Qian Wang, Xueli Guo, Guangmei Yang, Hongwei Zhang, Wei Chen\",\"doi\":\"10.2147/COPD.S524905\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The role of pharmacotherapy for alcohol use disorder (AUD) in mitigating COPD exacerbations remains underexplored. This study aims to evaluate the impact of AUD pharmacotherapy on COPD-related clinical outcomes.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted on 635 COPD patients with comorbid AUD. Patients were categorized into two groups based on whether they received medication for AUD (MAUD group) or not (no-MAUD group). Data on demographics, COPD severity, exacerbation rates, and AUD treatment were extracted from electronic medical records.</p><p><strong>Results: </strong>Individuals in the MAUD group (n=229) exhibited a substantially reduced frequency of COPD exacerbations when compared to those in the non-MAUD group (n=406), with a significant difference observed (<i>P</i><0.001). Additionally, the MAUD group experienced a longer duration before the first exacerbation event (<i>P</i><0.001).</p><p><strong>Conclusion: </strong>Pharmacotherapy for AUD appears to have a protective effect against the occurrence of COPD exacerbations and improved clinical outcomes in patients with comorbid AUD. These findings suggest that AUD treatment should be considered as part of a comprehensive management strategy for COPD patients with AUD.</p>\",\"PeriodicalId\":48818,\"journal\":{\"name\":\"International Journal of Chronic Obstructive Pulmonary Disease\",\"volume\":\"20 \",\"pages\":\"2697-2704\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-08-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333649/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Chronic Obstructive Pulmonary Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/COPD.S524905\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Chronic Obstructive Pulmonary Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/COPD.S524905","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
Breath and Bottle: Evaluating Pharmacotherapy for Alcohol Use Disorder on COPD Exacerbation Outcomes.
Background: The role of pharmacotherapy for alcohol use disorder (AUD) in mitigating COPD exacerbations remains underexplored. This study aims to evaluate the impact of AUD pharmacotherapy on COPD-related clinical outcomes.
Methods: A retrospective cohort study was conducted on 635 COPD patients with comorbid AUD. Patients were categorized into two groups based on whether they received medication for AUD (MAUD group) or not (no-MAUD group). Data on demographics, COPD severity, exacerbation rates, and AUD treatment were extracted from electronic medical records.
Results: Individuals in the MAUD group (n=229) exhibited a substantially reduced frequency of COPD exacerbations when compared to those in the non-MAUD group (n=406), with a significant difference observed (P<0.001). Additionally, the MAUD group experienced a longer duration before the first exacerbation event (P<0.001).
Conclusion: Pharmacotherapy for AUD appears to have a protective effect against the occurrence of COPD exacerbations and improved clinical outcomes in patients with comorbid AUD. These findings suggest that AUD treatment should be considered as part of a comprehensive management strategy for COPD patients with AUD.
期刊介绍：
An international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus will be given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is directed at specialists and healthcare professionals
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
